Structural features of α-synuclein amyloid fibrils revealed by Raman spectroscopy

Parkinson's disease (PD) is associated with the formation of α-synuclein amyloid fibrils. Elucidating the role of these β-sheet-rich fibrils in disease progression is crucial; however, collecting detailed structural information on amyloids is inherently difficult because of their insoluble, non-crystalline, and polymorphic nature. Here, we show that Raman spectroscopy is a facile technique for characterizing structural features of α-synuclein fibrils. Combining Raman spectroscopy with aggregation kinetics and transmission electron microscopy, we examined the effects of pH and ionic strength as well as four PD–related mutations (A30P, E46K, G51D, and A53T) on α-synuclein fibrils. Raman spectral differences were observed in the amide-I, amide-III, and fingerprint regions, indicating that secondary structure and tertiary contacts are influenced by pH and to a lesser extent by NaCl. Faster aggregation times appear to facilitate unique fibril structure as determined by the highly reproducible amide-I band widths, linking aggregation propensity and fibril polymorphism. Importantly, Raman spectroscopy revealed molecular-level perturbations of fibril conformation by the PD–related mutations that are not apparent through transmission electron microscopy or limited proteolysis. The amide-III band was found to be particularly sensitive, with G51D exhibiting the most distinctive features, followed by A53T and E46K. Relating to a cellular environment, our data would suggest that fibril polymorphs can be formed in different cellular compartments and potentially result in distinct phenotypes. Our work sets a foundation toward future cellular Raman studies of amyloids.

[1]  Jennifer C. Lee,et al.  Biophysics of α-synuclein membrane interactions. , 2012, Biochimica et biophysica acta.

[2]  D. Selkoe,et al.  In Vivo Cross-linking Reveals Principally Oligomeric Forms of α-Synuclein and β-Synuclein in Neurons and Non-neural Cells* , 2013, The Journal of Biological Chemistry.

[3]  T. Roemer,et al.  Antifungal drug development: challenges, unmet clinical needs, and new approaches. , 2014, Cold Spring Harbor perspectives in medicine.

[4]  C. Dobson,et al.  Protein misfolding, functional amyloid, and human disease. , 2006, Annual review of biochemistry.

[5]  Ronald Melki,et al.  G51D α‐synuclein mutation causes a novel Parkinsonian–pyramidal syndrome , 2013, Annals of neurology.

[6]  Houeto Jean-Luc [Parkinson's disease]. , 2022, La Revue du praticien.

[7]  E. Masliah,et al.  The many faces of α-synuclein: from structure and toxicity to therapeutic target , 2012, Nature Reviews Neuroscience.

[8]  Robert L. Nussbaum,et al.  Mutation in the α-Synuclein Gene Identified in Families with Parkinson's Disease , 1997 .

[9]  Saikat Ghosh,et al.  The Parkinson's disease-associated H50Q mutation accelerates α-Synuclein aggregation in vitro. , 2013, Biochemistry.

[10]  Peter T. Lansbury,et al.  Accelerated in vitro fibril formation by a mutant α-synuclein linked to early-onset Parkinson disease , 1998, Nature Medicine.

[11]  Paul R. Carey,et al.  Secondary Structure of α-Synuclein Oligomers: Characterization by Raman and Atomic Force Microscopy , 2006 .

[12]  Susan E Daniel,et al.  Characterisation of isolated α-synuclein filaments from substantia nigra of Parkinson's disease brain , 2000, Neuroscience Letters.

[13]  H. Levine Quantification of beta-sheet amyloid fibril structures with thioflavin T. , 1999, Methods in enzymology.

[14]  L. Serpell,et al.  Fiber diffraction of synthetic alpha-synuclein filaments shows amyloid-like cross-beta conformation. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[15]  R. Riek,et al.  Structure based aggregation studies reveal the presence of helix-rich intermediate during α-Synuclein aggregation , 2015, Scientific Reports.

[16]  Jennifer C. Lee,et al.  Taking a Bite Out of Amyloid: Mechanistic Insights into α-Synuclein Degradation by Cathepsin L. , 2017, Biochemistry.

[17]  Ewan W Blanch,et al.  A new perspective on beta-sheet structures using vibrational Raman optical activity: from poly(L-lysine) to the prion protein. , 2003, Journal of the American Chemical Society.

[18]  E. Valente,et al.  Phenotypic spectrum of alpha-synuclein mutations: New insights from patients and cellular models. , 2016, Parkinsonism & related disorders.

[19]  Nicholas K. Sauter,et al.  Structure of the toxic core of α-synuclein from invisible crystals , 2015, Nature.

[20]  M. Giugliano,et al.  α-Synuclein strains cause distinct synucleinopathies after local and systemic administration , 2015, Nature.

[21]  Nikolaos N. Louros,et al.  Tracking the amyloidogenic core of IAPP amyloid fibrils: Insights from micro-Raman spectroscopy. , 2017, Journal of structural biology.

[22]  Bernard Schneider,et al.  α-Synuclein in Central Nervous System and from Erythrocytes, Mammalian Cells, and Escherichia coli Exists Predominantly as Disordered Monomer* , 2012, The Journal of Biological Chemistry.

[23]  Jiajie Diao,et al.  Properties of native brain α-synuclein , 2013, Nature.

[24]  Andrew J. Nieuwkoop,et al.  Structured regions of α-synuclein fibrils include the early-onset Parkinson's disease mutation sites. , 2011, Journal of molecular biology.

[25]  V. Uversky,et al.  Is Congo Red an Amyloid-specific Dye?* , 2001, The Journal of Biological Chemistry.

[26]  Jennifer C. Lee,et al.  Tryptophan probes at the alpha-synuclein and membrane interface. , 2010, The journal of physical chemistry. B.

[27]  A. Steven,et al.  α-Synuclein Amyloid Fibrils with Two Entwined, Asymmetrically Associated Protofibrils* , 2015, The Journal of Biological Chemistry.

[28]  B. Meier,et al.  Structural and functional characterization of two alpha-synuclein strains , 2013, Nature Communications.

[29]  V. Uversky,et al.  Effect of familial Parkinson's disease point mutations A30P and A53T on the structural properties, aggregation, and fibrillation of human alpha-synuclein. , 2001, Biochemistry.

[30]  A. Talari,et al.  Raman Spectroscopy of Biological Tissues , 2007 .

[31]  Charles D. Schwieters,et al.  Solid-State NMR Structure of a Pathogenic Fibril of Full-Length Human α-Synuclein , 2016, Nature Structural &Molecular Biology.

[32]  Henning Stahlberg,et al.  The fold of α-synuclein fibrils , 2008, Proceedings of the National Academy of Sciences.

[33]  P. Lansbury,et al.  Fibrils formed in vitro from alpha-synuclein and two mutant forms linked to Parkinson's disease are typical amyloid. , 2000, Biochemistry.

[34]  T. Südhof,et al.  α-Synuclein assembles into higher-order multimers upon membrane binding to promote SNARE complex formation , 2014, Proceedings of the National Academy of Sciences.

[35]  Paul H. Axelsen,et al.  The E46K Mutation in α-Synuclein Increases Amyloid Fibril Formation* , 2005, Journal of Biological Chemistry.

[36]  M. Hosokawa,et al.  Fluorometric determination of amyloid fibrils in vitro using the fluorescent dye, thioflavin T1. , 1989, Analytical biochemistry.

[37]  Ashutosh Kumar,et al.  Perturbation in Long-Range Contacts Modulates the Kinetics of Amyloid Formation in α-Synuclein Familial Mutants. , 2017, ACS chemical neuroscience.

[38]  C. Rienstra,et al.  Preparation of alpha-synuclein fibrils for solid-state NMR: expression, purification, and incubation of wild-type and mutant forms. , 2006, Protein expression and purification.

[39]  M. Citron,et al.  Both Familial Parkinson’s Disease Mutations Accelerate α-Synuclein Aggregation* , 1999, The Journal of Biological Chemistry.

[40]  R. Melki,et al.  Structural and functional properties of prefibrillar α-synuclein oligomers , 2016, Scientific Reports.

[41]  Patrik Brundin,et al.  Pathogenesis of parkinson's disease: dopamine, vesicles and α-synuclein , 2002, Nature Reviews Neuroscience.

[42]  N. Maiti,et al.  Raman spectroscopic characterization of secondary structure in natively unfolded proteins: alpha-synuclein. , 2004, Journal of the American Chemical Society.

[43]  R. V. Van Duyne,et al.  Exploring the structure and formation mechanism of amyloid fibrils by Raman spectroscopy: a review. , 2015, The Analyst.

[44]  L. Serpell,et al.  Fiber diffraction of synthetic a-synuclein filaments shows amyloid-like cross-b conformation , 2000 .

[45]  S. Lane,et al.  Micro-Raman spectroscopy detects individual neoplastic and normal hematopoietic cells. , 2006, Biophysical journal.

[46]  S. Becker,et al.  Molecular-level secondary structure, polymorphism, and dynamics of full-length alpha-synuclein fibrils studied by solid-state NMR. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[47]  Jeannie Chen,et al.  Investigation of α-Synuclein Fibril Structure by Site-directed Spin Labeling* , 2007, Journal of Biological Chemistry.

[48]  L. Stefanis α-Synuclein in Parkinson's disease. , 2012, Cold Spring Harbor perspectives in medicine.

[49]  Jennifer C. Lee,et al.  Cysteine cathepsins are essential in lysosomal degradation of α-synuclein , 2015, Proceedings of the National Academy of Sciences.

[50]  H. Deng,et al.  Genetic variants and animal models in SNCA and Parkinson disease , 2014, Ageing Research Reviews.

[51]  H. Levine,et al.  Thioflavine T interaction with synthetic Alzheimer's disease β‐amyloid peptides: Detection of amyloid aggregation in solution , 1993, Protein science : a publication of the Protein Society.

[52]  P. Carey,et al.  Raman crystallography and other biochemical applications of Raman microscopy. , 2006, Annual review of physical chemistry.

[53]  V. Uversky,et al.  Evidence for a Partially Folded Intermediate in α-Synuclein Fibril Formation* , 2001, The Journal of Biological Chemistry.

[54]  A. Kaczor,et al.  Raman spectroscopy of proteins: a review , 2013 .